Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: Optimization by PEG size selection

Yu Seok Youn, Min Jung Kwon, Dong Hee Na, Su Young Chae, Seulki Lee, Kang Choon Lee

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to demonstrate the biological potentials of PEGylated salmon calcitonin (PEG-sCT) derivatives administered intratracheally and their dependences on PEG Mw (1, 2, 5 kDa). Initially, three different PEG-sCT derivatives were site-specifically synthesized by attaching PEG to the Lys18-amine. In an attempt to examine the pulmonary feasibilities of these derivatives, the following evaluations were undertaken to determine their; (i) proteolytic resistances to pulmonary enzymes, (ii) bioactivities, and (iii) pulmonary pharmacokinetic and pharmacologic profiles. The results obtained showed that the pulmonary stabilities and pharmacokinetic properties of these derivatives were greatly improved by increasing PEG Mw. PEG-sCTs had 10.5-, 40.1-, and 1066.0-fold greater stabilities than that of sCT in rat lung homogenates. Moreover, all pharmacokinetic parameters (AUCinf, Cmax, t1/2, and others) of these derivatives in endotracheally cannulated rats were significantly improved by PEGylation. Specifically, Cmax values increased on increasing PEG Mw, i.e., 78.1 ± 21.1, 102.9 ± 9.1, and 115.2 ± 5.7 for 1, 2, 5 kDa, respectively, vs. 54.8 ± 3.9 ng/mL for sCT. Their circulating t1/2 values also increased to 53.9 ± 6.0, 100.7 ± 21.7, and 119.4 ± 13.7 min, respectively, vs. 34.6 ± 7.6 min for sCT. Despite having the best properties, Lys18-PEG5k-sCT was found to have significantly lower hypocalcemic efficacy than other PEG-sCTs, probably due to its reduced intrinsic bioactivity (∼ 30% vs. sCT). Rather, Lys18-PEG2k-sCT showed the most promising pulmonary potential because of its well-preserved bioactivity (> 80% of sCT). Taken together, our findings suggest that the site-specific substitution to peptides like sCT with a PEG of an appropriate size offers optimized therapeutic potential by dual advantages, i.e., (i) increased proteolytic stability and (ii) extended circulating half-life in terms of intrapulmonary delivery.

Original languageEnglish (US)
Pages (from-to)68-75
Number of pages8
JournalJournal of Controlled Release
Volume125
Issue number1
DOIs
StatePublished - Jan 4 2008
Externally publishedYes

    Fingerprint

Keywords

  • Intrapulmonary delivery
  • PEGylation
  • Salmon calcitonin

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this